Brief: Everest Medicines Says Licensing Partner Pfizer Reports Positive Topline Results From Yearlong Phase 3 Trial Of Etrasimod In Ulcerative Colitis Patients
30/03/2022 01:06
March 29 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES - LICENSING PARTNER PFIZER REPORTS
POSITIVE
TOPLINE RESULTS FROM YEARLONG PHASE 3 TRIAL OF ETRASIMOD IN
ULCERATIVE COLITIS PATIENTS
* EVEREST MEDICINES LTD - PFIZER EXPECTS TO INITIATE
REGULATORY
FILINGS LATER THIS YEAR
Source text for Eikon: ID:nPn68lWXPa
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region